跳至主要内容
临床试验/CTRI/2024/06/068961
CTRI/2024/06/068961尚未招募2/3 期

Preclinical & Clinical evaluation Of Safety And Efficacy Of Mehmudgar Vati In The Management Of Madhumeha With Special reference To type 2 diabetes mellitus

National Institute of Ayurveda1 个研究点 分布在 1 个国家目标入组 90 人开始时间: 2024年7月1日最近更新:

试验速览

阶段
2/3 期
状态
尚未招募
入组人数
90
试验地点
1
主要终点
Changes in the objective parameters- F.B.S., P.P.B.S. HbA1c from

研究概览

简要总结

AIM

To evaluate the efficacy of Mehmudgara vati in Diabetes mellitus w.s.r to

Madhumeha

OBJECTIVES:

  1. Pre-clinical Study:

a. To evaluate the safety and efficacy of Mehmudgara Vati in Alloxan induced diabetes

mellitus in wistar albino rats.

b. To assess the effect of Mehmudgara Vati in beta cells (Islets of Langerhans) of

Pancreas through histopathological examination of the pancreatic cells in Alloxan

induced diabetes mellitus in wistar albino rats.

  1. Clinical Trial:

45

Primary Objectives:

  1. To evaluate and compare the effect of Mehmudgar Vati on blood glucose level

(FBS, PPBS) and HbA1c in Type -2 Diabetes Mellitus (Madhumeha) patients.

Secondary Objectives:

  1. To evaluate the effect of Mehmudgara vati on symptoms of Type -2 Diabetes

Mellitus (Madhumeha).

HYPOTHESIS:

ï‚· Null Hypothesis (Ho): There is no difference between effect of Mehmudgar Vati and

Metformin in the management of Madhumeha w.s.r. to Type -2 Diabetes Mellitus.

ï‚· Alternative Hypothesis (HA): There is difference between effect of Mehmudgar Vati

and Metformin in the management of Madhumeha w.s.r. to Type -2 Diabetes Mellitus.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
None

入排标准

年龄范围
30.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Patient ready to give consent for trial and willing to participate in the study
  • Patients between the age group of 30-60 years in either sex.
  • Patients with Fasting Blood Sugar (FBS) in the range of 126mg/dl – 200mg/dl or/and Post Prandial Blood Sugar (PPBS) in the range of 200mg/dl – 250 mg/dl.
  • Presence of Cardinal symptoms of Diabetes Mellitus eg.
  • (3P- polyuria, polydipsia, polyphagia).

排除标准

  • Patient not willing to sign the consent form.
  • Patients having Type-1 Diabetes Mellitus.
  • Patients of Type -2 Diabetes Mellitus who are on insulin therapy and Drug induced Diabetes Mellitus.
  • DM with complications and Madhumeha with asadhya upadrava.
  • Patients having any serious illness like cardiovascular diseases, renal diseases, hepatic diseases, acute/ chronic pancreatitis, malignancy, any other endocrinopathies .
  • Pregnant and lactating mother.
  • Patient on any other medications which may interfere with the effect of intervention.

结局指标

主要结局

Changes in the objective parameters- F.B.S., P.P.B.S. HbA1c from

时间窗: 18 weeks

baseline value.

时间窗: 18 weeks

次要结局

  • Changes in the clinical symptoms of Mahdumeha (Type 2 diabetes(mellitus))

研究者

申办方类型
Research institution
责任方
Principal Investigator
主要研究者

Babulal

National Institute of Ayurveda Deemed to be University, Jaipur

研究点 (1)

Loading locations...

相似试验